AI assistant

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Chemomab Therapeutics Ltd. Director's Dealing 2021

Mar 11, 2021

35107_dirs_2021-03-11_7c528934-8d88-4b41-a262-9ea310d5dc0d.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Anchiano Therapeutics Ltd. (ANCN)
CIK: 0001534248
Period of Report: 2020-04-23

Reporting Person: Cohen Neil Harris (Director, interim CEO)

Holdings (Non-Derivative)

Security	Shares	Ownership
Ordinary Shares	62110	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Warrant	$5.04	2023-03-29	Ordinary Shares (44935)		Direct

Footnotes

F1: This exercise price is in US Dollars and reflects the conversion of ILS to USD at an exchange rate of $1.00 to ILS 3.213 as published by the U.S. Department of Treasury on December 31, 2020.